Page last updated: 2024-11-04

sulforaphane and Hypertrophy, Left Ventricular

sulforaphane has been researched along with Hypertrophy, Left Ventricular in 2 studies

sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.

Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wu, QQ1
Zong, J1
Gao, L1
Dai, J1
Yang, Z1
Xu, M1
Fang, Y1
Ma, ZG1
Tang, QZ1
Bai, Y1
Cui, W1
Xin, Y1
Miao, X1
Barati, MT1
Zhang, C1
Chen, Q1
Tan, Y1
Cui, T1
Zheng, Y1
Cai, L1

Other Studies

2 other studies available for sulforaphane and Hypertrophy, Left Ventricular

ArticleYear
Sulforaphane protects H9c2 cardiomyocytes from angiotensin II-induced hypertrophy.
    Herz, 2014, Volume: 39, Issue:3

    Topics: Angiotensin II; Animals; Cardiotonic Agents; Cell Line; Cell Size; Cell Survival; Dose-Response Rela

2014
Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation.
    Journal of molecular and cellular cardiology, 2013, Volume: 57

    Topics: Animals; Catalase; Cell Line; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diab

2013